The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

ADT with leuprolide was tied to increased coronary plaque vs relugolix in prostate cancer. What does this mean for CV risk?

Prostate cancer has been one of the major areas of research for radioligand therapies. Last year, Novartis officials estimated that the March 28, 2025, FDA approval for Pluvicto in metastatic ...

Step by step, little by little, we are learning how to act on this new staging information,’ one investigator says.

Prostate cancer is among the most prevalent cancers in men, particularly above the age of 50. In India, prostate cancer has been increasingly reported, with the urban population being at a higher risk ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

When it comes to detecting cancer, you want the fastest detection possible in order to treat it accurately and in a timely ...

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...